Discovery of a Potent and Selective CDKL5/GSK3 Chemical Probe That Is Neuroprotective
- PMID: 37084253
- PMCID: PMC10161233
- DOI: 10.1021/acschemneuro.3c00135
Discovery of a Potent and Selective CDKL5/GSK3 Chemical Probe That Is Neuroprotective
Abstract
Despite mediating several essential processes in the brain, including during development, cyclin-dependent kinase-like 5 (CDKL5) remains a poorly characterized human protein kinase. Accordingly, its substrates, functions, and regulatory mechanisms have not been fully described. We realized that availability of a potent and selective small molecule probe targeting CDKL5 could enable illumination of its roles in normal development as well as in diseases where it has become aberrant due to mutation. We prepared analogs of AT-7519, a compound that has advanced to phase II clinical trials and is a known inhibitor of several cyclin-dependent kinases (CDKs) and cyclin-dependent kinase-like kinases (CDKLs). We identified analog 2 as a highly potent and cell-active chemical probe for CDKL5/GSK3 (glycogen synthase kinase 3). Evaluation of its kinome-wide selectivity confirmed that analog 2 demonstrates excellent selectivity and only retains GSK3α/β affinity. We next demonstrated the inhibition of downstream CDKL5 and GSK3α/β signaling and solved a co-crystal structure of analog 2 bound to human CDKL5. A structurally similar analog (4) proved to lack CDKL5 affinity and maintain potent and selective inhibition of GSK3α/β, making it a suitable negative control. Finally, we used our chemical probe pair (2 and 4) to demonstrate that inhibition of CDKL5 and/or GSK3α/β promotes the survival of human motor neurons exposed to endoplasmic reticulum stress. We have demonstrated a neuroprotective phenotype elicited by our chemical probe pair and exemplified the utility of our compounds to characterize the role of CDKL5/GSK3 in neurons and beyond.
Keywords: CDKL5; GSK3α; GSK3β; chemical probe; crystal structure; kinase; neuroprotective.
Conflict of interest statement
The authors declare no competing financial interest.
Figures











Update of
-
A Potent and Selective CDKL5/GSK3 Chemical Probe is Neuroprotective.bioRxiv [Preprint]. 2023 Feb 10:2023.02.09.527935. doi: 10.1101/2023.02.09.527935. bioRxiv. 2023. Update in: ACS Chem Neurosci. 2023 May 3;14(9):1672-1685. doi: 10.1021/acschemneuro.3c00135. PMID: 36798313 Free PMC article. Updated. Preprint.
Similar articles
-
A Potent and Selective CDKL5/GSK3 Chemical Probe is Neuroprotective.bioRxiv [Preprint]. 2023 Feb 10:2023.02.09.527935. doi: 10.1101/2023.02.09.527935. bioRxiv. 2023. Update in: ACS Chem Neurosci. 2023 May 3;14(9):1672-1685. doi: 10.1021/acschemneuro.3c00135. PMID: 36798313 Free PMC article. Updated. Preprint.
-
Discovery and characterization of a specific inhibitor of serine-threonine kinase cyclin-dependent kinase-like 5 (CDKL5) demonstrates role in hippocampal CA1 physiology.Elife. 2023 Jul 25;12:e88206. doi: 10.7554/eLife.88206. Elife. 2023. PMID: 37490324 Free PMC article.
-
Elucidation of the GSK3α Structure Informs the Design of Novel, Paralog-Selective Inhibitors.ACS Chem Neurosci. 2023 Mar 15;14(6):1080-1094. doi: 10.1021/acschemneuro.2c00476. Epub 2023 Feb 22. ACS Chem Neurosci. 2023. PMID: 36812145 Free PMC article.
-
GSK3α: An Important Paralog in Neurodegenerative Disorders and Cancer.Biomolecules. 2020 Dec 16;10(12):1683. doi: 10.3390/biom10121683. Biomolecules. 2020. PMID: 33339170 Free PMC article. Review.
-
Cyclin-Dependent Kinase-Like 5 (CDKL5): Possible Cellular Signalling Targets and Involvement in CDKL5 Deficiency Disorder.Neural Plast. 2020 Jun 5;2020:6970190. doi: 10.1155/2020/6970190. eCollection 2020. Neural Plast. 2020. PMID: 32587608 Free PMC article. Review.
Cited by
-
Bacterial Production of CDKL5 Catalytic Domain: Insights in Aggregation, Internal Translation and Phosphorylation Patterns.Int J Mol Sci. 2024 Aug 15;25(16):8891. doi: 10.3390/ijms25168891. Int J Mol Sci. 2024. PMID: 39201578 Free PMC article.
-
Identifying dysregulated regions in amyotrophic lateral sclerosis through chromatin accessibility outliers.HGG Adv. 2024 Jul 18;5(3):100318. doi: 10.1016/j.xhgg.2024.100318. Epub 2024 Jun 13. HGG Adv. 2024. PMID: 38872308 Free PMC article.
-
Illumination of understudied ciliary kinases.Front Mol Biosci. 2024 Mar 8;11:1352781. doi: 10.3389/fmolb.2024.1352781. eCollection 2024. Front Mol Biosci. 2024. PMID: 38523660 Free PMC article. Review.
-
A phylogenetic analysis of the CDKL protein family unravels its evolutionary history and supports the Drosophila model of CDKL5 deficiency disorder.Front Cell Dev Biol. 2025 Apr 30;13:1582684. doi: 10.3389/fcell.2025.1582684. eCollection 2025. Front Cell Dev Biol. 2025. PMID: 40371392 Free PMC article.
-
Role of the CDKL1-SOX11 signaling axis in acute kidney injury.Am J Physiol Renal Physiol. 2024 Sep 1;327(3):F426-F434. doi: 10.1152/ajprenal.00147.2024. Epub 2024 Jul 11. Am J Physiol Renal Physiol. 2024. PMID: 38991010
References
-
- Ricciardi S.; Ungaro F.; Hambrock M.; Rademacher N.; Stefanelli G.; Brambilla D.; Sessa A.; Magagnotti C.; Bachi A.; Giarda E.; et al. CDKL5 ensures excitatory synapse stability by reinforcing NGL-1-PSD95 interaction in the postsynaptic compartment and is impaired in patient iPSC-derived neurons. Nat. Cell Biol. 2012, 14, 911–923. 10.1038/ncb2566. - DOI - PMC - PubMed
-
- Fuchs C.; Trazzi S.; Torricella R.; Viggiano R.; De Franceschi M.; Amendola E.; Gross C.; Calzà L.; Bartesaghi R.; Ciani E. Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3β signaling. Neurobiol. Dis. 2014, 70, 53–68. 10.1016/j.nbd.2014.06.006. - DOI - PMC - PubMed
-
- Barbiero I.; Valente D.; Chandola C.; Magi F.; Bergo A.; Monteonofrio L.; Tramarin M.; Fazzari M.; Soddu S.; Landsberger N.; Rinaldo C.; Kilstrup-Nielsen C. CDKL5 localizes at the centrosome and midbody and is required for faithful cell division. Sci. Rep. 2017, 7, 6228.10.1038/s41598-017-05875-z. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources